This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 13.89% and 11.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 8th
by Zacks Equity Research
AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025.
New Strong Sell Stocks for April 3rd
by Zacks Equity Research
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
by Zacks Equity Research
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
by Zacks Equity Research
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
Here's Why Agios Stock Plummeted More Than 20% on Monday
by Zacks Equity Research
The fall in AGIO stock comes after reports of an unexpected side effect linked to its sole-marketed drug Pyrukynd in thalassemia patients.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
by Zacks Equity Research
ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
by Zacks Equity Research
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -74.84% and 4.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
by Zacks Equity Research
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
by Zacks Equity Research
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.